SCA
OMED

Secor Capital Advisors’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Secor Capital Advisors’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-26,380
Closed -$203K – 679
2016
Q4 		$203K Buy
+26,380
New +$242K 0.02% 450

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Secor Capital Advisors's OMED Position: Q1 2017 in Review

Secor Capital Advisors sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2017, closing a stake of 26,380 shares — an estimated $203K sold.

Secor Capital Advisors first reported a position in OMED in Q4 2016 and held it in 1 quarter. The position peaked at $203K in Q4 2016. 85 funds tracked by Wall St. Rank hold OMED as of Q1 2017.

  • Secor Capital Advisors reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Secor Capital Advisors sold 26,380 OncoMed Pharmaceuticals, Inc. shares in Q1 2017, an estimated $203K.
  • Secor Capital Advisors first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
  • Secor Capital Advisors's OncoMed Pharmaceuticals, Inc. position peaked at $203K in Q4 2016.
  • 85 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2017.

Based on Secor Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.